Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
- 31 October 2013
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 13 (5), 559-567
- https://doi.org/10.1016/j.clml.2013.03.019
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 23 references indexed in Scilit:
- Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumorsAnnals Of Oncology, 2010
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivoCancer Research, 2009
- Mitotic drivers—inhibitors of the Aurora B KinaseCancer and Metastasis Reviews, 2009
- Independent prognostic factors for AML outcomeHematology, 2009
- Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blastsHaematologica, 2008
- Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st centuryHaematologica, 2008
- A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemiaMolecular Cancer Therapeutics, 2007
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 1999